Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10005514 | 0.92 | AKR1C3 (0.40) | PDE3BPDE3ARPS6KA3AKR1C3AKR1C2 | |
| SCHEMBL12889472 | 0.88 | PTGS2 (0.40) | PDE3BPDE3ARPS6KA3AKR1C3AKR1C2 | |
| SCHEMBL18069657 | 0.87 | PDE3B (0.40) | PDE3BPDE3AAKR1C3AKR1C2GRM2 | |
| SCHEMBL17359262 | 0.86 | RPS6KA3 (0.46) | PDE3BPDE3ARPS6KA3PTGS2 | |
| SCHEMBL18069655 | 0.86 | AKR1C3 (0.46) | PDE3BPDE3AAKR1C3AKR1C2GRM2 | |
| SCHEMBL17359299 | 0.86 | CYP2A6 (0.45) | PDE3BPDE3ARPS6KA3AKR1C3AKR1C2 | |
| SCHEMBL18069661 | 0.85 | PTGS2 (0.43) | PDE3BPDE3ARPS6KA3GRM2PTGS2 | |
| SCHEMBL17359249 | 0.84 | PTGS2 (0.37) | PDE3BPDE3AAKR1C3AKR1C2PTGS2 | |
| SCHEMBL13295485 | 0.83 | PDE3B (0.41) | PDE3BPDE3ARPS6KA3AKR1C3AKR1C2 | |
| SCHEMBL13097600 | 0.83 | PDE3B (0.41) | PDE3BPDE3ARPS6KA3AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527870-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX3, OCIAD1, PIEZO1 | PDE3B 644/4885PDE3A 463/4885RPS6KA3 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.